Paladin Capital Group Marks Another Successful Exit in Sale of QuantaLife
QuantaLife, one of the nation’s most promising life sciences companies, was purchased this week by Bio-Rad Laboratories for $162 million – marking another successful exit for Paladin Capital Group. Paladin helped nurture QuantaLife from a tiny startup with a great idea to a dynamic company that is helping to accelerate the search for causes, cures and diagnostics for many important diseases, including cancer, HIV and genetic birth defects.
CyberCore Welcomes Paladin Capital Group as New Investor
CyberCore Technologies (“CyberCore”), a leading provider of information technology services to the federal government and intelligence community with expertise in cyber security, systems integration and secure supply chain management, today announced that the Paladin Capital Group has made an investment in the company. The investment comes after Cybercore was acquired by Moelis Capital Partners (MCP), the private equity business affiliated with Moelis & Company, in July.